248 related articles for article (PubMed ID: 35164339)
1. The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164339
[TBL] [Abstract][Full Text] [Related]
2. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
Torre BG; Albericio F
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504104
[TBL] [Abstract][Full Text] [Related]
3. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
[TBL] [Abstract][Full Text] [Related]
4. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
[TBL] [Abstract][Full Text] [Related]
5. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
[TBL] [Abstract][Full Text] [Related]
6. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
G de la Torre B; Albericio F
Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
[TBL] [Abstract][Full Text] [Related]
7. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
de la Torre BG; Albericio F
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
[TBL] [Abstract][Full Text] [Related]
8. The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.
Torre BG; Albericio F
Molecules; 2017 Feb; 22(3):. PubMed ID: 28264468
[TBL] [Abstract][Full Text] [Related]
9. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Al Shaer D; Al Musaimi O; Albericio F; de la Torre BG
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215334
[TBL] [Abstract][Full Text] [Related]
10. FDA Approvals of Biologics in 2022.
Martins AC; Albericio F; de la Torre BG
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239105
[TBL] [Abstract][Full Text] [Related]
11. 2023 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
[TBL] [Abstract][Full Text] [Related]
12. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
13. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
14. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
16. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
17. Recent drug approvals from the US FDA and EMEA: what the future holds.
Pevarello P
Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
[TBL] [Abstract][Full Text] [Related]
18. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
19. US-FDA Approved Drugs in 2020 and 2021: A Review.
Passi I; Salwan S; Kumar B
Mini Rev Med Chem; 2023; 23(12):1273-1297. PubMed ID: 36503454
[TBL] [Abstract][Full Text] [Related]
20. 2022 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
